{"preliminary_commentary":{"by_channel":{"youtube":8,"podcast":5,"x_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06660654\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"REJOICE-PanTumor01","nct_id":"NCT06660654","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=rejoice-pantumor01-nct06660654. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants with endometrial cancer who will receive raludotatug deruxtecan (R-DXd) administered intravenously every 3 weeks (Q3W).","label":"Endometrial Cancer Cohort","type":"EXPERIMENTAL"},{"description":"Participants with cervical cancer who will receive R-DXd administered intravenously Q3W.","label":"Cervical Cancer Cohort","type":"EXPERIMENTAL"},{"description":"Participants with non-high-grade serous ovarian cancer who will receive R-DXd administered intravenously Q3W.","label":"Non-high-grade Serous Ovarian Cancer","type":"EXPERIMENTAL"},{"description":"Participants with urothelial cancer who will receive R-DXd administered intravenously Q3W.","label":"Urothelial Cancer Cohort","type":"EXPERIMENTAL"},{"description":"Participants with clear cell renal carcinoma (ccRCC) who will receive R-DXd administered intravenously Q3W.","label":"Clear Cell Renal Carcinoma (ccRCC) Cohort","type":"EXPERIMENTAL"}],"collaborators":["Merck Sharp & Dohme LLC"],"completion_date":{"date":"2029-12-30","type":"ESTIMATED"},"conditions":["Advanced Solid Tumor","Metastatic Solid Tumors"],"enrollment":{"count":335,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Raludotatug deruxtecan","otherNames":["R-DXd"],"type":"DRUG"}],"last_update":"2026-09-24","lead_sponsor":"Daiichi Sankyo","official_title":"REJOICE-PanTumor01: A Phase 2, Multicenter, Open-Label, Pan-Tumor Trial to Evaluate Efficacy and Safety of Raludotatug Deruxtecan (R-DXd) in Participants With Advanced/Metastatic Solid Tumors","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2029-12-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Objective Response Rate as Assessed by the Investigator (All Cohorts Except ccRCC)","timeFrame":"Baseline up to 48 months"},{"measure":"Disease Control Rate (DCR) as Assessed by the Investigator (ccRCC Cohort Only)","timeFrame":"Baseline up to 48 months"},{"measure":"Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESIs) (All Cohorts)","timeFrame":"Baseline up to 48 months"}],"references":[],"start_date":{"date":"2025-01-06","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)","url":"https://clinicaltrials.gov/study/NCT06660654"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/rejoice-pantumor01-nct06660654"}